{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:24:57Z","timestamp":1794918297564,"version":"4.9.1"},"reference-count":48,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T00:00:00Z","timestamp":1631059200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Gut"],"accepted":{"date-parts":[[2021,6,24]]},"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1136\/gutjnl-2020-323931","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T13:20:46Z","timestamp":1631107246000},"page":"2196-2204","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["Alternative treatments for type 2 diabetes and associated metabolic diseases: medical therapy or endoscopic duodenal mucosal remodelling?"],"prefix":"10.1136","volume":"70","author":[{"given":"Annieke C G","family":"van Baar","sequence":"first","affiliation":[{"name":"Gastroenterology and Hepatology, Amsterdam UMC Location AMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Meiring","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology, Amsterdam UMC Location AMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits","family":"Holleman","sequence":"additional","affiliation":[{"name":"Internal Medicine, Amsterdam UMC Location AMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hopkins","sequence":"additional","affiliation":[{"name":"Institute of Diabetes, Endocrinology and Obesity, King's Health Partners, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2021-528X","authenticated-orcid":false,"given":"Geltrude","family":"Mingrone","sequence":"additional","affiliation":[{"name":"Internal Medicine, Universita Cattolica del Sacro Cuore, Rome, Italy"},{"name":"Diabetes, King's College London School of Medical Education, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Devi\u00e8re","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatopancreatology, Erasme University Hospital, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1926-7659","authenticated-orcid":false,"given":"Max","family":"Nieuwdorp","sequence":"additional","affiliation":[{"name":"Vascular Medicine, Amsterdam UMC Location AMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7548-6955","authenticated-orcid":false,"given":"Jacques J G H M","family":"Bergman","sequence":"additional","affiliation":[{"name":"Gastroenterology and Hepatology, Amsterdam UMC Location AMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,9,8]]},"reference":[{"key":"2025121303154293000_70.11.2196.1","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.4.1270"},{"key":"2025121303154293000_70.11.2196.2","unstructured":"NHS Digital . National diabetes audit programme, 2021. Available: https:\/\/digital.nhs.uk\/data-and-information\/clinical-audits-and-registries\/national-diabetes-audit"},{"key":"2025121303154293000_70.11.2196.3","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S006"},{"key":"2025121303154293000_70.11.2196.4","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.metabol.2018.01.003","article-title":"Effects of a combined dietary, exercise and behavioral intervention and sympathetic system on body weight maintenance after intended weight loss: results of a randomized controlled trial","volume":"83","author":"Mai","year":"2018","journal-title":"Metabolism"},{"key":"2025121303154293000_70.11.2196.5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/oby.20662","article-title":"Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study","volume":"22","year":"2014","journal-title":"Obesity"},{"key":"2025121303154293000_70.11.2196.6","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4318-z"},{"key":"2025121303154293000_70.11.2196.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07037-8"},{"key":"2025121303154293000_70.11.2196.8","article-title":"Metformin monotherapy for type 2 diabetes mellitus","author":"Saenz","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121303154293000_70.11.2196.9","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1007\/s00125-017-4336-x","article-title":"Metformin: clinical use in type 2 diabetes","volume":"60","author":"Sanchez-Rangel","year":"2017","journal-title":"Diabetologia"},{"key":"2025121303154293000_70.11.2196.10","first-page":"487","article-title":"Update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD)","volume":"2020","author":"Buse","year":"2019","journal-title":"Diabetes Care"},{"key":"2025121303154293000_70.11.2196.11","doi-asserted-by":"publisher","DOI":"10.1007\/BF02427280"},{"key":"2025121303154293000_70.11.2196.12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/dom.13162","article-title":"A review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomised controlled trials","volume":"20(Suppl 1)","author":"Aroda","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2025121303154293000_70.11.2196.13","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-8587(19)30249-9","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials","volume":"7","author":"Kristensen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025121303154293000_70.11.2196.14","unstructured":"Bolen S , Tseng E , Hutfless S . Diabetes medications for adults with type 2 diabetes: an update. Rockville, MD, 2016."},{"key":"2025121303154293000_70.11.2196.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2016.02.146"},{"key":"2025121303154293000_70.11.2196.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501352"},{"key":"2025121303154293000_70.11.2196.17","doi-asserted-by":"crossref","first-page":"1155-1166","DOI":"10.1001\/jama.2019.13772","article-title":"Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the Carolina randomized clinical trial","volume":"322","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"2025121303154293000_70.11.2196.18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00592-016-0892-7","article-title":"Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials","volume":"54","author":"Monami","year":"2017","journal-title":"Acta Diabetol"},{"key":"2025121303154293000_70.11.2196.19","first-page":"199","article-title":"Effects of SGLT2 inhibitors on weight loss in patients with type 2 diabetes mellitus","volume":"21","author":"Ribola","year":"2017","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2025121303154293000_70.11.2196.20","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.166.17.1802"},{"key":"2025121303154293000_70.11.2196.21","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/DMSO.S120101","article-title":"Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015","volume":"9","author":"Higgins","year":"2016","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2025121303154293000_70.11.2196.22","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0487"},{"key":"2025121303154293000_70.11.2196.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1600869"},{"key":"2025121303154293000_70.11.2196.24","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1007\/s00464-020-07555-y","article-title":"Clinical practice guidelines of the European association for endoscopic surgery (EAES) on bariatric surgery: update 2020 endorsed by IFSO-EC, EASO and ESPCOP","volume":"34","author":"Di Lorenzo","year":"2020","journal-title":"Surg Endosc"},{"key":"2025121303154293000_70.11.2196.25","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s00125-017-4513-y","article-title":"Metabolic surgery for the treatment of type 2 diabetes in obese individuals","volume":"61","author":"Cummings","year":"2018","journal-title":"Diabetologia"},{"key":"2025121303154293000_70.11.2196.26","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ijsu.2016.01.067","article-title":"Complications of bariatric surgery: presentation and emergency management","volume":"27","author":"Kassir","year":"2016","journal-title":"Int J Surg"},{"key":"2025121303154293000_70.11.2196.27","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.02.010"},{"key":"2025121303154293000_70.11.2196.28","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.gie.2019.03.024","article-title":"Duodenal mucosal resurfacing: proof-of-concept, procedural development, and initial implementation in the clinical setting","volume":"90","author":"Haidry","year":"2019","journal-title":"Gastrointest Endosc"},{"key":"2025121303154293000_70.11.2196.29","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0383"},{"key":"2025121303154293000_70.11.2196.30","doi-asserted-by":"crossref","first-page":"E1683","DOI":"10.1055\/a-1244-2283","article-title":"Duodenal mucosal resurfacing: multicenter experience implementing a minimally invasive endoscopic procedure for treatment of type 2 diabetes mellitus","volume":"8","author":"van Baar","year":"2020","journal-title":"Endosc Int Open"},{"key":"2025121303154293000_70.11.2196.31","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318349"},{"key":"2025121303154293000_70.11.2196.32","unstructured":"van Baar ACG , Lopez-Talavera JC , White K . Durable glycemic and hepatic improvements after duodenal mucosal resurfacing in patients with type 2 diabetes. J Diabetes Sci Technol 2020:A115."},{"key":"2025121303154293000_70.11.2196.33","article-title":"Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial","author":"Mingrone","year":"2021","journal-title":"Gut"},{"key":"2025121303154293000_70.11.2196.34","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.gie.2020.12.021","article-title":"Duodenal mucosal resurfacing combined with glucagon-like peptide-1 receptor agonism to discontinue insulin in type 2 diabetes: a feasibility study","volume":"94","author":"van Baar","year":"2021","journal-title":"Gastrointest Endosc"},{"key":"2025121303154293000_70.11.2196.35","doi-asserted-by":"crossref","unstructured":"Dimitriadis GK , Kaur V , P\u00e9rez-Pevida B , et al . Investigation of the mechanism of action of duodenal mucosal resurfacing in insulin resistant women with polycystic ovarian syndrome. The domino multicentre randomised controlled trial. Endocrine Abstracts 2020;70.doi:10.1530\/endoabs.70.AEP799","DOI":"10.1530\/endoabs.70.AEP799"},{"key":"2025121303154293000_70.11.2196.36","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/dom.12971","article-title":"Effect of weight reduction on glycated haemoglobin in weight loss trials in patients with type 2 diabetes","volume":"19","author":"Gummesson","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"2025121303154293000_70.11.2196.37","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.tige.2020.03.003","article-title":"Small intestinal physiology relevant to bariatric and metabolic endoscopic therapies: incretins, bile acid signaling, and gut microbiome","volume":"22","author":"van Olst","year":"2020","journal-title":"Tech Innov Gastrointest Endosc"},{"key":"2025121303154293000_70.11.2196.38","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jhepr.2019.10.006","article-title":"Endoscopic duodenal mucosal resurfacing improves glycaemic and hepatic indices in type 2 diabetes: 6-month multicentre results","volume":"1","author":"van Baar","year":"2019","journal-title":"JHEP Rep"},{"key":"2025121303154293000_70.11.2196.39","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-09-0101"},{"key":"2025121303154293000_70.11.2196.40","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(20)32649-0","article-title":"Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial","volume":"397","author":"Mingrone","year":"2021","journal-title":"Lancet"},{"key":"2025121303154293000_70.11.2196.41","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2454"},{"key":"2025121303154293000_70.11.2196.42","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1745"},{"key":"2025121303154293000_70.11.2196.43","first-page":"523","article-title":"A prospective study of concomitant GLP-1 analogue and insulin use in type 2 diabetes in clinical practice","volume":"72","author":"van Velsen","year":"2014","journal-title":"Neth J Med"},{"key":"2025121303154293000_70.11.2196.44","unstructured":"Clinicaltrials.Gov . Evaluation of the efficacy and safety of duodenal mucosal resurfacing using the Revita\u00ae system in subjects with type 2 diabetes on insulin therapy (REVITA-T2Di). Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04419779"},{"key":"2025121303154293000_70.11.2196.45","doi-asserted-by":"crossref","DOI":"10.2337\/db19-1131-P","article-title":"1131-P: endoscopic duodenal submucosal laser ablation for the treatment of type 2 diabetes mellitus: results of first-in-human pilot study","volume":"68","author":"MRAZ","year":"2019","journal-title":"Diabetes"},{"key":"2025121303154293000_70.11.2196.46","unstructured":"ClinicalTrials.Gov . Safety and feasibility of a novel endoscopic intervention for the treatment of type II diabetes (REGENT-1). Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04725890"},{"key":"2025121303154293000_70.11.2196.47","unstructured":"Netherlands Trial Register . Trial NL9482. Available: https:\/\/www.trialregister.nl\/trial\/9482"},{"key":"2025121303154293000_70.11.2196.48","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-17-0438"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gutjnl-2020-323931","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T11:15:49Z","timestamp":1765624549000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gutjnl-2020-323931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,8]]},"references-count":48,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,10,7]]},"published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1136\/gutjnl-2020-323931"],"URL":"https:\/\/doi.org\/10.1136\/gutjnl-2020-323931","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,8]]}}}